ZAHO-Siegburg
- Address
- Humperdinckstraße 10-12, 53721 Siegburg, Germany
ZAHO-Siegburg - Multiple Myeloma Research Center
ZAHO-Siegburg is a specialized clinical research facility dedicated to advancing treatment approaches for hematologic malignancies, with particular emphasis on multiple myeloma. The center participates in cutting-edge Phase III trials evaluating novel therapeutic combinations and drug delivery methods to optimize patient outcomes.
- Multiple myeloma treatment optimization and immunotherapy research
- Drug delivery system comparisons for monoclonal antibodies
- Novel combination therapies including isatuximab with lenalidomide, bortezomib, and dexamethasone
The center's research portfolio focuses on demonstrating non-inferiority of alternative administration routes to improve patient convenience and quality of life. By evaluating subcutaneous versus intravenous delivery of targeted therapies in newly diagnosed multiple myeloma patients, ZAHO-Siegburg contributes to establishing evidence-based standards that balance treatment efficacy with patient-centered care considerations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in ZAHO-Siegburg
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase III Non-Inferiority Trial of Lenalidomide, Bortezomib, Dexamethasone, and Isatuximab in Newly Diagnosed Multiple Myeloma Patients | Universitaetsklinikum Heidelberg AöR | Phase III | Not Recruiting | Mar 2023 | Jan 2026 |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Betamethasone Sodium Phosphate | 1 | Unknown | 2023-03-07 | 2023-03-07 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.